JP2010521458A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521458A5
JP2010521458A5 JP2009553600A JP2009553600A JP2010521458A5 JP 2010521458 A5 JP2010521458 A5 JP 2010521458A5 JP 2009553600 A JP2009553600 A JP 2009553600A JP 2009553600 A JP2009553600 A JP 2009553600A JP 2010521458 A5 JP2010521458 A5 JP 2010521458A5
Authority
JP
Japan
Prior art keywords
group
trifluoromethyl
ylamino
pyridin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009553600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521458A (ja
JP5569956B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003205 external-priority patent/WO2008115369A2/en
Publication of JP2010521458A publication Critical patent/JP2010521458A/ja
Publication of JP2010521458A5 publication Critical patent/JP2010521458A5/ja
Application granted granted Critical
Publication of JP5569956B2 publication Critical patent/JP5569956B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009553600A 2007-03-16 2008-03-10 接着斑キナーゼのインヒビター Expired - Fee Related JP5569956B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89537907P 2007-03-16 2007-03-16
US60/895,379 2007-03-16
US94663707P 2007-06-27 2007-06-27
US60/946,637 2007-06-27
US3002508P 2008-02-20 2008-02-20
US61/030,025 2008-02-20
PCT/US2008/003205 WO2008115369A2 (en) 2007-03-16 2008-03-10 Inhibitors of focal adhesion kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014104005A Division JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Publications (3)

Publication Number Publication Date
JP2010521458A JP2010521458A (ja) 2010-06-24
JP2010521458A5 true JP2010521458A5 (2) 2011-05-06
JP5569956B2 JP5569956B2 (ja) 2014-08-13

Family

ID=39628767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009553600A Expired - Fee Related JP5569956B2 (ja) 2007-03-16 2008-03-10 接着斑キナーゼのインヒビター
JP2014104005A Pending JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014104005A Pending JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Country Status (10)

Country Link
US (2) US8501763B2 (2)
EP (2) EP2727909A1 (2)
JP (2) JP5569956B2 (2)
CN (2) CN101679264A (2)
CA (1) CA2681015C (2)
DK (1) DK2134689T3 (2)
ES (1) ES2485040T3 (2)
PL (1) PL2134689T3 (2)
TW (2) TWI536991B (2)
WO (1) WO2008115369A2 (2)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010014057A (es) 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010067987A2 (ko) * 2008-12-10 2010-06-17 동화약품주식회사 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
CN102648197A (zh) * 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
MX340819B (es) * 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
MX343894B (es) * 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Síntesis y uso de inhibidores de cinasa.
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
MX2013008654A (es) * 2011-01-26 2013-09-02 Glaxosmithkline Intellectual Property Ltd Combinaciones.
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
RU2659786C2 (ru) * 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
CA2907912A1 (en) * 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
WO2015035199A1 (en) * 2013-09-06 2015-03-12 Mayo Foundation For Medical Education And Research Neem compositions used for the treatment of cancer
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
JP2018519327A (ja) 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
KR20180070696A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2를 억제하는 피롤로-, 피라졸로-, 이미다조-피리미딘 및 피리딘 화합물
SG11201803242TA (en) 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
LT3380465T (lt) 2015-11-26 2020-11-10 Novartis Ag Diamino piridino dariniai
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
BR112019016707A2 (pt) 2017-02-14 2020-04-07 Effector Therapeutics Inc inibidores de mnk substituídos por piperidina e métodos relacionados aos mesmos
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
AU2019348011A1 (en) * 2018-09-27 2021-02-11 Dana-Farber Cancer Institute, Inc. Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use
TWI857981B (zh) 2018-10-24 2024-10-11 美商伊凡克特治療公司 Ｍｎｋ抑制劑的結晶形式
CN110724137B (zh) * 2019-11-13 2021-03-30 广东工业大学 一种噻吩类衍生物及其制备方法与应用
CN111233834B (zh) * 2020-03-09 2021-08-31 北京师范大学 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
CN117222634A (zh) * 2020-12-16 2023-12-12 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
GB202113079D0 (en) * 2021-09-14 2021-10-27 Ucl Business Ltd New therapy
WO2023218245A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof
CN121335887A (zh) * 2023-06-08 2026-01-13 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4064671B2 (ja) * 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CN101535276B (zh) 2006-10-23 2013-08-28 赛福伦公司 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
EP2311807B1 (en) * 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
BRPI0720264B1 (pt) 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Similar Documents

Publication Publication Date Title
JP5569956B2 (ja) 接着斑キナーゼのインヒビター
JP2010521458A5 (2)
RU2615130C2 (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
AU2014367283B2 (en) Maleimide derivatives as modulators of WNT pathway
BRPI0716918A2 (pt) Composto, composição farmacêutica, composição farmacêutica embalada, método de tratar um paciente que apresente uma doença responsiva à inibição da atividade btk, método de tratar um paciente que apresente uma doença escolhida dentre câncer, doenças autoimunes, reações inflamatórias agudas e transtornos alérgicos, método de aumentar a sensibilidade de células cancerosas à quimioterapia, método de reduzir o erro de medicação e melhorar o cumprimento terapêutico de um paciente sendo tratado para uma doença responsiva à inibição da atividade btk, método de inibir a hidrólise de atp, método para determinar a presença de btk em uma amostra, método de inibir a atividade de células-b
CN101072755A (zh) Hedgehog信号转导的吡啶基抑制剂
WO2008150446A1 (en) Inhibitors of protein kinases
CN103539784A (zh) 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015187094A1 (en) Phthalimide derivatives as modulators of wnt pathway
HK1141521A (en) Inhibitors of focal adhesion kinase
HK1194380B (en) Inhibitors of focal adhesion kinase
HK1194380A (en) Inhibitors of focal adhesion kinase
CN119816492A (zh) Trpv2通道阻断剂及其用途
TW202237082A (zh) 安諾特明６（Ａｎｏｃｔａｍｉｎ ６）之抑制劑及其用途
HK1183019A (en) Pyridyl inhibitors of hedgehog signalling